Stocks News

LAST PRICE
26.4300
TODAY'S CHANGE (%)
Trending Up0.0300 (0.1136%)

Bid / Lots
26.3000/ 4
Ask / Lots
26.4800/ 2
Open / Previous Close
26.3800 / 26.4000
Day Range
Low 26.3300
High 26.6300
52 Week Range
Low 25.1001
High 31.6550
Volume
2,461,717
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 14, 2024
- Royalty Pharma Announces Inaugural Prize for Impact in Healthcare, from 4:30PM ET on Thursday Nov 14, 2024 by Dow Jones
  4:30PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: RPRX
  
  Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
  -- Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the Prostate Cancer Foundation -- The Prize includes a charitable donation to further fund medical research
Nov 7, 2024
- Geron Secures up to $375 Million in Funding with Royalty Pharma, Pharmakon Advisors, from 11:42AM ET on Thursday Nov 07, 2024 by MT Newswires
  11:42AM ET on Thursday Nov 07, 2024 by MT Newswires
  Companies Mentioned: GERN, RPRX
  11:42 AM EST, 11/07/2024 (MT Newswires) -- Geron (GERN) said Thursday it secured up to $375 million in synthetic royalty and debt financings with Royalty Pharma (RPRX) and investment funds managed by Pharmakon Advisors. The company said $250 million...
- Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million, from 7:10AM ET on Thursday Nov 07, 2024 by Dow Jones
  7:10AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: GERN, RPRX
  
  Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million
  -- RYTELO(TM) (imetelstat) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia -- Transaction increases Royalty Pharma's synthetic royalty funding to $925 million in 2024, highlighting the significant opportunity for this attractive funding modality
Nov 6, 2024
- Royalty Pharma Q3 Net Income, Revenue Climb; Shares Rise Pre-Bell, from 8:08AM ET on Wednesday Nov 06, 2024 by MT Newswires
  8:08AM ET on Wednesday Nov 06, 2024 by MT Newswires
  Companies Mentioned: RPRX
  08:08 AM EST, 11/06/2024 (MT Newswires) -- Royalty Pharma (RPRX) reported Q3 net income Wednesday of $544 million, up from $72 million a year earlier. Comparable analysts' estimates were not available. Total income and other revenue for the quarter ...
- -- Earnings Flash (RPRX) ROYALTY PHARMA Posts Q3 Revenue $565M, from 7:18AM ET on Wednesday Nov 06, 2024 by MT Newswires
  7:18AM ET on Wednesday Nov 06, 2024 by MT Newswires
  Companies Mentioned: RPRX
  07:18 AM EST, 11/06/2024 (MT Newswires) -- ...

Today
- Sector Update: Health Care Stocks Advance Premarket Friday, from 10 hours ago by MT Newswires
  10 hours ago by MT Newswires
  Companies Mentioned: AMRX, HALO, IBB, EVO, XLV, EYEN
- DJ Jazz Pharmaceuticals Price Target Maintained With a $200.00/Share by HC Wainwright & Co., from 14 hours ago by Dow Jones
  14 hours ago by Dow Jones
  Companies Mentioned: JAZZ
Yesterday
- Amneal Pharmaceuticals Gets FDA Nod for Diabetes Injections, Resubmits Application for Migraine Treatment, from 5:16PM ET on Thursday Nov 21, 2024 by MT Newswires
  5:16PM ET on Thursday Nov 21, 2024 by MT Newswires
  Companies Mentioned: AMRX
- DJ Amneal Resubmits New Drug Application for Migraine Treatment, Diabetes Drug Is Approved, from 5:05PM ET on Thursday Nov 21, 2024 by Dow Jones
  5:05PM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: AMRX
- Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist, from 4:05PM ET on Thursday Nov 21, 2024 by Dow Jones
  4:05PM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: AMRX
- DJ Jazz Pharmaceuticals Price Target Maintained With a $207.00/Share by Needham, from 1:06PM ET on Thursday Nov 21, 2024 by Dow Jones
  1:06PM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: JAZZ
- DJ Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK, from 9:30AM ET on Thursday Nov 21, 2024 by Dow Jones
  9:30AM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: JAZZ, ZYME, BGNE
- Sector Update: Health Care Stocks Rise Pre-Bell Thursday, from 9:13AM ET on Thursday Nov 21, 2024 by MT Newswires
  9:13AM ET on Thursday Nov 21, 2024 by MT Newswires
  Companies Mentioned: IBB, JAZZ, PFE, XLV, ZYME, ZLAB, NRIX
- DJ Jazz Pharmaceuticals Price Target Cut to $163.00/Share From $166.00 by Piper Sandler, from 9:06AM ET on Thursday Nov 21, 2024 by Dow Jones
  9:06AM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: JAZZ
- Sector Update: Health Care, from 8:52AM ET on Thursday Nov 21, 2024 by MT Newswires
  8:52AM ET on Thursday Nov 21, 2024 by MT Newswires
  Companies Mentioned: JAZZ, ZYME

Royalty Pharma PLC
NASDAQ:RPRXUnited States

Search Criteria

Nov 14, 2024

Royalty Pharma Announces Inaugural Prize for Impact in Healthcare, from 4:30PM ET on Thursday Nov 14, 2024 by Dow Jones

Nov 7, 2024

Geron Secures up to $375 Million in Funding with Royalty Pharma, Pharmakon Advisors, from 11:42AM ET on Thursday Nov 07, 2024 by MT Newswires

Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million, from 7:10AM ET on Thursday Nov 07, 2024 by Dow Jones

Nov 6, 2024

Royalty Pharma Q3 Net Income, Revenue Climb; Shares Rise Pre-Bell, from 8:08AM ET on Wednesday Nov 06, 2024 by MT Newswires

-- Earnings Flash (RPRX) ROYALTY PHARMA Posts Q3 Revenue $565M, from 7:18AM ET on Wednesday Nov 06, 2024 by MT Newswires

Peers Headlines

Today

Sector Update: Health Care Stocks Advance Premarket Friday, from 10 hours ago by MT Newswires

DJ Jazz Pharmaceuticals Price Target Maintained With a $200.00/Share by HC Wainwright & Co., from 14 hours ago by Dow Jones

Yesterday

Amneal Pharmaceuticals Gets FDA Nod for Diabetes Injections, Resubmits Application for Migraine Treatment, from 5:16PM ET on Thursday Nov 21, 2024 by MT Newswires

DJ Amneal Resubmits New Drug Application for Migraine Treatment, Diabetes Drug Is Approved, from 5:05PM ET on Thursday Nov 21, 2024 by Dow Jones

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist, from 4:05PM ET on Thursday Nov 21, 2024 by Dow Jones

DJ Jazz Pharmaceuticals Price Target Maintained With a $207.00/Share by Needham, from 1:06PM ET on Thursday Nov 21, 2024 by Dow Jones

DJ Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK, from 9:30AM ET on Thursday Nov 21, 2024 by Dow Jones

Sector Update: Health Care Stocks Rise Pre-Bell Thursday, from 9:13AM ET on Thursday Nov 21, 2024 by MT Newswires

DJ Jazz Pharmaceuticals Price Target Cut to $163.00/Share From $166.00 by Piper Sandler, from 9:06AM ET on Thursday Nov 21, 2024 by Dow Jones

Sector Update: Health Care, from 8:52AM ET on Thursday Nov 21, 2024 by MT Newswires